STK11 mutation was associated with a specific “cold” tumor immune microenvironment (TIME), characterized by production of pro-inflammatory cytokines, decrease in tumor-infiltrating CD8+ lymphocytes and low PD-L1 expression on tumor cells (Koyama et al., 2016). The gene discussed is CD8A; the disease is neoplasm.